Dentsply Sirona Q2 adjusted EPS of $0.52 beats $0.36 consensus; guidance maintained
Question
Dentsply Sirona Q2 adjusted EPS of $0.52 beats $0.36 consensus; guidance maintained
Direct answer
Operating cost controls and Wellspect revenue resilience offset dental equipment softness to protect XRAY's FY2026 EPS range of $1.40-$1.50. — bullish pressure on XRAY via operating margin preservation lifting adjusted earnings realization.
- Original publisher
- Market Ontology
- Evidence through
- 2026-09-09
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Dentsply Sirona Q2 adjusted EPS of $0.52 beats $0.36 consensus; guidance maintained”, revision 1, evidence through 2026-09-09. https://marketontology.com/catalysts/2026-09-09/dentsply-sirona-q2-adjusted-eps-of-0-52-beats-0-36-consensus-guidance-maintained-0c2ce4
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| XRAY | ▲Bull | 1–5 days | operating margin preservation lifting adjusted earnings realization | 49 |
Dentsply Sirona Q2 adjusted EPS of $0.52 beats $0.36 consensus; guidance maintained
Operating cost controls and Wellspect revenue resilience offset dental equipment softness to protect XRAY's FY2026 EPS range of $1.40-$1.50. — bullish pressure on XRAY via operating margin preservation lifting adjusted earnings realization.
Q2 EPS beat consensus at $0.52 vs $0.36 and FY2026 outlook was reaffirmed.
- SourceQ2 EPS beat consensus at $0.52 vs $0.36 and FY2026 outlook was reaffirmed.
- TransmissionOperating cost controls and Wellspect revenue resilience offset dental equipment softness to protect XRAY's FY2026 EPS range of $1.40-$1.50.
- SummaryDentsply Sirona delivered Q2 adjusted EPS of $0.52 versus $0.36 expected. Full-year sales guidance held at $3.5B to $3.6B with adjusted EPS at $1.40 to $1.50. Wellspect Healthcare grew 7.1% while dental equipment revenues contracted 4.1%.
- XRAYDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- Sector rotation or peer guidance may override single-name reaction
- XRAY closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- XRAY price vs. pre-event level
- XRAY volume vs. 20-day average
- Sector ETF read-through
- Options implied volatility crush
What happened next
| Asset | Call | Base close | +1 day | +5 days | +20 days |
|---|---|---|---|---|---|
| XRAY | Bullishdisagreed | 10.72 2026-09-09 | -2.05% | -5.41% | Pending |
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- XRAY's Q2 Earnings Beat Meets Steady Guidance and Margin Pressure · news_wire · 2026-09-08
Related catalysts
- 2026-09-09Dentsply Sirona Beats Q2 EPS at $0.52 vs $0.36 Consensus and Affirms FY26 OutlookALGN XRAY-5.41%
- 2026-09-09Dentsply Sirona Beats Q2 EPS at $0.52 and Affirms FY2026 Sales GuidanceALGN XRAY-5.41%
- 2026-09-09Dentsply Sirona Tops Q2 EPS at $0.52 vs $0.36 Consensus and Affirms FY2026 GuidanceALGN XRAY-5.41%
- 2026-09-09Dentsply Sirona Beats Q2 EPS Estimates at $0.52 and Reaffirms FY2026 TargetsXRAY-5.41%
- 2026-09-09Dentsply Sirona Beats Q2 EPS at $0.52 and Reaffirms FY26 Sales OutlookXRAY-5.41%
- 2026-09-09Dentsply Sirona reports Q2 adjusted EPS of $0.52 and maintains $3.5B-$3.6B sales outlookALGN XRAY-5.41%
- 2026-09-09Dentsply Sirona Q2 EPS Beats at $0.52 Despite 4.1% Revenue ContractionXRAY-5.41%
- 2026-09-09Dentsply Sirona Beats Q2 EPS at $0.52 and Reaffirms FY26 Sales OutlookXRAY-5.41%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.